---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029236"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:43:16.565891+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia

## Summary
- First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.
- OLE to assess long-term safety, pharmacokinetics, and tissue frataxin levels; initial data expected Q4 2024.
- Frataxin data from OLE and prior studies intended to support BLA for accelerated approval targeted H2 2025.
- Nomlabofusp remains under partial clinical hold; 50 mg cohort data will be submitted to FDA for dose escalation review.

## SEC filing metadata
- accession: 0000950170-24-029236
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024029236/0000950170-24-029236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024029236/lrmr-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029236
- JSON: https://secwatch.observer/filing/0000950170-24-029236.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.